Evidence map›Paper›PMID 26068241›Full record

ArticleNitric oxide : biology and chemistry2015

Inhibition of endogenous hydrogen sulfide production in clear-cell renal cell carcinoma cell lines and xenografts restricts their growth, survival and angiogenic potential.

Eric Sonke, Megan Verrydt, Carl O Postenka, Siddika Pardhan, Chantalle J Willie, Clarisse R Mazzola, Matthew D Hammers, Michael D Pluth, Ian Lobb, Nicholas E Power and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nitric oxide : biology and chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The Triple Crown: NO, CO, and HPharmacology & therapeutics · 2023
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Hydrogen Sulfide Actions in the Vasculature.Comprehensive Physiology · 2021
    Article
  10. Molecular Functions of Hydrogen Sulfide in Cancer.Pathophysiology : the official journal of the International Society for Pathophysiology · 2021
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Vascular biology of hydrogen sulfide.American journal of physiology. Cell physiology · 2017
    Review
  16. Review
  17. Article
  18. Patterns of Expression of HIn vivo (Athens, Greece)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Eric SonkeDepartment of Anatomy & Cell Biology, Schulich Medicine and Dentistry, Medical Sciences Building Room 443, Western University, London, Ontario N6A 5C1, Canada; Matthew Mailing Centre for Translational Transplant Studies, 339 Windermere Rd., London Health Sciences Centre, London, Ontario N6A 5A5, Canada. Electronic address: esonke@uwo.ca.
Megan VerrydtMatthew Mailing Centre for Translational Transplant Studies, 339 Windermere Rd., London Health Sciences Centre, London, Ontario N6A 5A5, Canada; Department of Biology, 1151 Richmond St., Western University, London, Ontario N6A 5B7, Canada. Electronic address: mverrydt@uwo.ca.
Carl O PostenkaLondon Regional Cancer Program, 790 Commissioners Rd. E, London Health Sciences Centre, London, Ontario N6A 5A5, Canada. Electronic address: cpostenk@uwo.ca.
Siddika PardhanDepartment of Surgery, Schulich Medicine and Dentistry, 268 Grosvenor St., St Joseph's Hospital, London, Ontario N6A 4V2, Canada; Translational Prostate Cancer Research Laboratory, F3-124, 268 Grosvenor St., St Joseph's Hospital, London, Ontario N6A 4V2, Canada. Electronic address: siddika.15@gmail.com.
Chantalle J WillieDepartment of Surgery, Schulich Medicine and Dentistry, 268 Grosvenor St., St Joseph's Hospital, London, Ontario N6A 4V2, Canada; Translational Prostate Cancer Research Laboratory, F3-124, 268 Grosvenor St., St Joseph's Hospital, London, Ontario N6A 4V2, Canada. Electronic address: chantalle.willie@gmail.com.
Clarisse R MazzolaDepartment of Surgery, Schulich Medicine and Dentistry, 268 Grosvenor St., St Joseph's Hospital, London, Ontario N6A 4V2, Canada. Electronic address: mazzola_clarisse@hotmail.fr.
Matthew D HammersDepartment of Chemistry & Biochemistry, 1253 University of Oregon, University of Oregon, Eugene, OR 97403, USA. Electronic address: mhammers@uoregon.edu.
Michael D PluthDepartment of Chemistry & Biochemistry, 1253 University of Oregon, University of Oregon, Eugene, OR 97403, USA. Electronic address: pluth@uoregon.edu.
Ian LobbMatthew Mailing Centre for Translational Transplant Studies, 339 Windermere Rd., London Health Sciences Centre, London, Ontario N6A 5A5, Canada; Department of Microbiology and Immunology, Schulich Medicine and Dentistry, Dental Sciences Building Room 3014, Western University, London, Ontario N6A 5C1, Canada; Schulich School of Medicine and Dentistry, Clinical Skills Building, Western University, London, Ontario N6A 5C1, Canada. Electronic address: ilobb@uwo.ca.
Nicholas E PowerDepartment of Surgery, Schulich Medicine and Dentistry, 268 Grosvenor St., St Joseph's Hospital, London, Ontario N6A 4V2, Canada; Department of Oncology, Schulich Medicine and Dentistry, 790 Commissioners Rd. E Room A4901, London Regional Cancer Program, London, Ontario N6A 4L6, Canada. Electronic address: nicholas.power@lhsc.on.ca.
Ann F ChambersLondon Regional Cancer Program, 790 Commissioners Rd. E, London Health Sciences Centre, London, Ontario N6A 5A5, Canada; Department of Oncology, Schulich Medicine and Dentistry, 790 Commissioners Rd. E Room A4901, London Regional Cancer Program, London, Ontario N6A 4L6, Canada. Electronic address: ann.chambers@lhsc.on.ca.
Hon S LeongDepartment of Surgery, Schulich Medicine and Dentistry, 268 Grosvenor St., St Joseph's Hospital, London, Ontario N6A 4V2, Canada; Translational Prostate Cancer Research Laboratory, F3-124, 268 Grosvenor St., St Joseph's Hospital, London, Ontario N6A 4V2, Canada; Department of Microbiology and Immunology, Schulich Medicine and Dentistry, Dental Sciences Building Room 3014, Western University, London, Ontario N6A 5C1, Canada. Electronic address: hon.leong@lhsc.on.ca.
Alp SenerMatthew Mailing Centre for Translational Transplant Studies, 339 Windermere Rd., London Health Sciences Centre, London, Ontario N6A 5A5, Canada; Department of Surgery, Schulich Medicine and Dentistry, 268 Grosvenor St., St Joseph's Hospital, London, Ontario N6A 4V2, Canada; Department of Microbiology and Immunology, Schulich Medicine and Dentistry, Dental Sciences Building Room 3014, Western University, London, Ontario N6A 5C1, Canada; Schulich School of Medicine and Dentistry, Clinical Skills Building, Western University, London, Ontario N6A 5C1, Canada; Multiorgan Transplant Program, 339 Windermere Rd., London Health Sciences Centre, London, Ontario N6A 5A5, Canada. Electronic address: alp.sener@lhsc.on.ca.
London Health Sciences Centre · CASt. Joseph's Hospital · CAWestern University · CACancer Care Ontario · CAUniversity of Oregon · US

Funding

Angiopathy Training GrantT32HL094295 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MARS, WENDY MICHELLE · 2010 to 2014
$1.2M
Developing fluorescent probes for the endogenous gaseous transmitters NO and H2SR00GM092970 · NIGMS · UNIVERSITY OF OREGON · PI PLUTH, MICHAEL · 2011 to 2013
$731k
NHLBI NIH HHS NIH T32 HL094295NIGMS NIH HHS R00 GM092970
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is characterized by Von Hippel-Lindau (VHL)-deficiency, resulting in pseudohypoxic, angiogenic and glycolytic tumours. Hydrogen sulfide (H2S) is an endogenously-produced gasotransmitter that accumulates under hypoxia and has been shown to be pro-angiogenic and cytoprotective in cancer. It was hypothesized that H2S levels are elevated in VHL-deficient ccRCC, contributing to survival, metabolism and angiogenesis. Using the H2S-specific probe MeRhoAz, it was found that H2S levels were higher in VHL-deficient ccRCC cell lines compared to cells with wild-type VHL. Inhibition of H2S-producing enzymes could reduce the proliferation, metabolism and survival of ccRCC cell lines, as determined by live-cell imaging, XTT/ATP assay, and flow cytometry respectively. Using the chorioallantoic membrane angiogenesis model, it was found that systemic inhibition of endogenous H2S production was able to decrease vascularization of VHL-deficient ccRCC xenografts. Endogenous H2S production is an attractive new target in ccRCC due to its involvement in multiple aspects of disease.

Indexed as

AnimalsCarcinoma, Renal CellCell Line, TumorCell ProliferationCell SurvivalChick EmbryoHumansHydrogen SulfideNeovascularization, PathologicXenograft Model Antitumor AssaysHydrogen SulfideAngiogenesisCell hypoxiaCell metabolismCell survivalClear cell renal cell carcinomaHydrogen sulfide

Identifiers

PMID26068241
PMCPMC4876030
OpenAlexW2192373688

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.